This inventor holds 1 USPTO granted patent. Top assignees: Kobe University, Osaka Prefectural Hospital Organization, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 143 
1 out of 9 
1 out of 4 Years Active: 2021
Title: Innovator in Glycobiology: The Work of Motoi Kanagawa
Introduction
Motoi Kanagawa, an inventive mind based in Hyogo, Japan, has significantly contributed to the field of glycobiology. His focused research has led to advancements in therapeutic approaches for diseases associated with abnormalities in dystroglycan sugar chain modification.
Latest Patents
Kanagawa holds a noteworthy patent titled "Therapeutic agent for diseases associated with abnormalities in dystroglycan sugar chain modification and method for assaying associated enzyme". This patent outlines a therapeutic agent that utilizes CDP-ribitol as an active ingredient to address diseases caused by abnormal glycosylation of dystroglycan. The discovery that CDP-ribitol serves as a crucial sugar donor for glycan structure formation in dystroglycan is a pivotal advancement in the field. The invention demonstrates the ability to restore glycan functionality in ISPD-deficient cells through the administration of CDP-ribitol, offering a promising pathway for supplementation therapy.
Career Highlights
Throughout his career, Motoi Kanagawa has collaborated with prestigious institutions such as Kobe University and Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology. His work at these establishments has been vital in exploring the nuances of glycobiology and its implications for treating age-related and genetic diseases.
Collaborations
Kanagawa has had the opportunity to work alongside notable colleagues, including Tatsushi Toda and Kazuhiro Kobayashi. Together, they have contributed to essential research that delves into the complexities of glycosylation and its impact on human health.
Conclusion
Motoi Kanagawa's innovative efforts in the field of glycobiology exemplify the significant role of research in developing therapeutic strategies for complex diseases. With his groundbreaking patent and collaborations, Kanagawa continues to pave the way for future advancements in understanding and treating conditions linked to dystroglycan abnormalities. His work is a testament to the importance of scientific inquiry and innovation in enhancing human health and wellbeing.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile